Tagged with Biosecure Act

Uncertain Future for Biosecure Act, US-China Biopharma Relations

USA Uncertain Future for Biosecure Act, US-China Biopharma Relations

USA The Biosecure Act has been excluded from a recent key defense spending bill, leaving its future unclear. But whether or not it ends up being passed, the legislation has already proved detrimental for the targeted Chinese companies and the new Trump administration’s “America first” stance may have other adverse effects…

Building a Resilient Future: How the Bioeconomy Strengthens US Security and Growth

USA Building a Resilient Future: How the Bioeconomy Strengthens US Security and Growth

USA Monica Weldon, a seasoned rare disease patient advocate in the US, now serves as the lead strategic analyst for the life science industry base policy at Leidos, a technology solutions firm. Here, she explains the rationale behind the Biden administration’s Executive Order 14081 from 2022, as well as its impact…

BIO Chair Ted Love on IRA, US Election Outcomes & the Biosecure Act

USA BIO Chair Ted Love on IRA, US Election Outcomes & the Biosecure Act

USA At the American trade association’s latest CEO & Investor Conference, the board chair of the Biotechnology Innovation Organization (BIO) Ted W. Love discussed US policies and speculated about the impact of the upcoming American election on the industry while affirming that biotech continues to thrive in spite of recent challenges.…

New US ‘Biosecure Act’ to Target Chinese Biotechs WuXi and BGI

USA New US ‘Biosecure Act’ to Target Chinese Biotechs WuXi and BGI

USA US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is now targeting these companies and the potential impact of a proposed US Biosecure Act on US-China biotech ties. Protecting…

China Pharma News: US Bill Pinpoints WuXi as “Foreign Adversary Biotech;” Novartis Acquires SanReno

China China Pharma News: US Bill Pinpoints WuXi as “Foreign Adversary Biotech;” Novartis Acquires SanReno

China The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics; the first orphan drug designation for a Chinese herbal medicine-based therapy, and AstraZeneca’s new production line in Taizhou. Eisai…